Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer.

**Background:** Treatment options for patients with platinum resistant ovarian cancer [PROC] are limited. Immune checkpoint inhibitors (ICI) have limited activity in PROC, therefore clinical studies evaluating novel therapies are urgently needed. We have previously reported durable partial responses and a complete response with COM701 +/- BMS986207 + nivolumab\(^1\). COM701 is a novel, 1\(^{st}\) in-class ICI binding to PVRIG, that leads to activation of T-cells. BMS-986207 is an ICI blocker of TIGIT. We report longer term follow-up showing continued durable responses in pts with PROC treated with a triple immunotherapy combination blocking the DNAM-1 axis with COM701 + BMS-986207 + nivolumab (NCT04570839).

Stephanie Gaillard, MD, PhD1, Manish Sharma, MD2, Daniel Vaena, MD3, Oladapo Yeku, MD, PhD4, Drew Rasco, MD5, Ecaterina Dumbrava6, Kyriakos P Papadopoulos, MD7, Amita Patnaik, MD8, Ryan Sullivan, MD9, Benjamin Izar, PhD10, Pierre Ferre, PhD11, Eran Ophir, PhD12, Inbal Barbiro, PhD13, Gady Cojocaru, PhD14, Adeboye H Adewoye, MD14 and John Moroney, MD15.


**Methods:** We enrolled 20 patients with PROC treated with COM701 20 mg/kg + BMS-986207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives were safety/tolerability; secondary objective was preliminary antitumor activity of the combination. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard treatments. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-(L)-1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0.

**Results:** No new safety signals are reported. The combination is well tolerated. There were 4/20 [20%] patients with confirmed PR and 5 pts with SD with a DCR [CR+PR+SD] 9/20 [45%], no CRs. Median [med] age 61yr, med number of prior lines of therapy - 4 [range 1-10]. Histology of patients with PR – high grade serous adenocarcinoma [3 pts], clear cell histology [1 pt]. Three pts continue study treatment at 449, 428 and 477 days, 1 pt with high grade serous adenocarcinoma was on study treatment for 222 days.

**Conclusion:** Continued durable confirmed partial responses by blocking the DNAM-1 axis with the combination of COM701 + BMS-986207 + nivolumab in pts with heavily pre-treated PROC. Additional translational data will be presented at the conference. Data extract 06/09/2023.
Study sponsored by Compugen Ltd in collaboration with Bristol Myers Squibb.